CureVac N.V. (CVAC) –
-
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
-
Form 6-K CureVac N.V. For: Apr 16
-
CureVac (CVAC) and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
-
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
-
Form 144 CureVac N.V. Filed by: Greune Malte
-
Form 6-K CureVac N.V. For: Apr 04
-
CureVac N.V. (CVAC) Reports Promising Phase 2 Interim Data
-
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
-
Form SC 13G/A CureVac N.V. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A CureVac N.V. Filed by: GSK plc
-
CureVac N.V. (CVAC): CEO Alexander Zehnder Acquires 50,000 Common Shares
-
Form 6-K CureVac N.V. For: Jan 17
-
Form 6-K CureVac N.V. For: Jan 05
-
Form 144 CureVac N.V. Filed by: Mendila Myriam
-
Form 144 CureVac N.V. Filed by: Zehnder Alexander
-
Form 144 CureVac N.V. Filed by: Greune Malte
-
Form 144 CureVac N.V. Filed by: Kemula Pierre
-
CureVac N.V. (CVAC) Reports Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK
-
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
-
Form 6-K CureVac N.V. For: Dec 19
-
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
-
CureVac N.V. (CVAC) Announces Decision of German Patent Court in Litigation with BioNTech (BNTX)
-
CureVac (CVAC) Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech (BNTX)
-
Why CureVac (CVAC) stock just dropped 30%
-
CureVac N.V. (CVAC) sinks as German court sides with BioNTech (BNTX) in patent case
-
Form 6-K CureVac N.V. For: Nov 14
-
Form 6-K CureVac N.V. For: Sep 30
-
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
-
Form 6-K CureVac N.V. For: Nov 01
-
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
-
Form 20-F/A CureVac N.V. For: Dec 31
-
Form 6-K CureVac N.V. For: Sep 28
-
Form 6-K CureVac N.V. For: Sep 12
-
CureVac N.V. (CVAC) Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
-
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
-
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
-
Form 6-K CureVac N.V. For: Jun 30
-
Form 6-K CureVac N.V. For: Aug 17
-
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
-
Form 6-K CureVac N.V. For: Aug 01
-
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
-
Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology
-
Form 6-K CureVac N.V. For: Jul 14
-
CureVac N.V. (CVAC) Announces Update to the Management Team
-
CureVac Announces Update to the Management Team
-
Form 6-K CureVac N.V. For: Jul 13
-
CureVac (CVAC) has strengthened its position in the ongoing patent litigations
-
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
-
Form 6-K CureVac N.V. For: Jun 22
-
Form 6-K CureVac N.V. For: Jun 20
Back to CVAC Stock Lookup
